Clinical use and monitoring of adverse effects of sodium‐glucose cotransporter‐2 inhibitors in persons with type 1 diabetes mellitus
When initiating SGLT2i in T1DM patients, it is important to evaluate glycemic control and adjust insulin dosage based on weight and diabetes duration to reduce hypoglycemia frequency.
Authors
- Keiji Sugai (ORCID: https://orcid.org/0000-0003-0354-0849)
- Ryo Suzuki (ORCID: https://orcid.org/0000-0002-2965-6906)
- Hironori Takeuchi (ORCID: https://orcid.org/0000-0002-0954-6988)
- Chikara Sakai
- Shinichi Tamaru
Institutions
- Tokyo Medical University (JP)
- Tokyo Medical University Hospital (JP)
Publication Details
- Journal
- Journal of Diabetes Investigation
- Published
- 2025-05-26
- DOI
- https://doi.org/10.1111/jdi.70085
- Citations
- 2
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 2.59
Funders
- Takeda Pharmaceutical Company
- Kowa Company
- Dainippon Sumitomo Pharma
- Astellas Pharma
- Teijin Pharma
- Mitsubishi Tanabe Pharma Corporation
- Ono Pharmaceutical
- MSD K.K.
- Eli Lilly Japan
- Novo Nordisk Pharma
- Sanofi K.K.
- Daiichi Sankyo Company